AR100459A1 - Una composición farmacéutica antiviral de uso tópico - Google Patents

Una composición farmacéutica antiviral de uso tópico

Info

Publication number
AR100459A1
AR100459A1 ARP150101519A ARP150101519A AR100459A1 AR 100459 A1 AR100459 A1 AR 100459A1 AR P150101519 A ARP150101519 A AR P150101519A AR P150101519 A ARP150101519 A AR P150101519A AR 100459 A1 AR100459 A1 AR 100459A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
cationic
methacrylate
groups
weight
Prior art date
Application number
ARP150101519A
Other languages
English (en)
Inventor
Alberto Argaars Luis
Original Assignee
Química Luar S R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Química Luar S R L filed Critical Química Luar S R L
Priority to ARP150101519A priority Critical patent/AR100459A1/es
Priority to MX2017014162A priority patent/MX384814B/es
Priority to US15/573,901 priority patent/US10478452B2/en
Priority to PCT/ES2016/070365 priority patent/WO2016185069A1/es
Priority to BR112017024399-7A priority patent/BR112017024399B1/pt
Priority to ES16795937T priority patent/ES2915824T3/es
Priority to EP16795937.8A priority patent/EP3295934B1/en
Priority to PE2017002343A priority patent/PE20180396A1/es
Publication of AR100459A1 publication Critical patent/AR100459A1/es
Priority to CONC2017/0011297A priority patent/CO2017011297A2/es
Priority to CL2017002796A priority patent/CL2017002796A1/es
Priority to IL255635A priority patent/IL255635A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una composición farmacéutica antiviral de uso tópico contra aquellos virus con envoltura lipídica, que comprende como principios activos un copolímero catiónico conteniendo grupos aminos terciarios, y un tensioactivo catiónico conteniendo grupos amonios cuaternarios. Reivindicación 2: La composición farmacéutica de la reivindicación 1 caracterizada porque además comprende un agente facilitador del paso a través de piel que contiene grupos azufres, un polímero catiónico de alto peso molecular para aportar la viscosidad necesaria para permitir mayor tiempo de residencia en el lugar aplicado y un anestésico de uso local. Reivindicación 4: La composición farmacéutica de la reivindicación 1 caracterizada porque dicho copolímero catiónico comprende Poli(butil-metacrilato-co-(2-dimetilaminoetil)metacrilato-co-metil metacrilato) 1:2:1. Reivindicación 8: La composición farmacéutica de la reivindicación 1 caracterizada porque dicho tensioactivo catiónico conteniendo grupos aminos cuaternarios comprende cloruro de cetil piridinio. Reivindicación 11: La composición farmacéutica de la reivindicación 2 caracterizada porque dicho agente facilitador del paso a través de piel que contiene grupos azufres comprende dimetilsulfóxido en una concentración de entre el 2 y el 35% en peso. Reivindicación 14: La composición farmacéutica de la reivindicación 2 caracterizada porque dicho anestésico de uso local es seleccionado del conjunto comprendido por lidocaína, xilocaína y sus mezclas en una concentración de entre el 1 y el 15% en peso. Reivindicación 17: La composición farmacéutica de la reivindicación 2 caracterizada porque dicho polímero catiónico de alto peso molecular para aportar la viscosidad necesaria para permitir mayor tiempo de residencia en el lugar aplicado comprende poliquaternium 10 (Nº CAS: 81859-24-7).
ARP150101519A 2015-05-15 2015-05-15 Una composición farmacéutica antiviral de uso tópico AR100459A1 (es)

Priority Applications (11)

Application Number Priority Date Filing Date Title
ARP150101519A AR100459A1 (es) 2015-05-15 2015-05-15 Una composición farmacéutica antiviral de uso tópico
ES16795937T ES2915824T3 (es) 2015-05-15 2016-05-13 Composición farmacéutica antiviral de uso tópico
US15/573,901 US10478452B2 (en) 2015-05-15 2016-05-13 Antiviral pharmaceutical composition for topical use
PCT/ES2016/070365 WO2016185069A1 (es) 2015-05-15 2016-05-13 Una composición farmacéutica antiviral de uso tópico
BR112017024399-7A BR112017024399B1 (pt) 2015-05-15 2016-05-13 Composição farmacêutica antiviral de uso tópico
MX2017014162A MX384814B (es) 2015-05-15 2016-05-13 Composición farmacéutica antiviral de uso tópico que comprende copolímero catónico y tensoactivo catónico.
EP16795937.8A EP3295934B1 (en) 2015-05-15 2016-05-13 Antiviral pharmaceutical composition for topical use
PE2017002343A PE20180396A1 (es) 2015-05-15 2016-05-13 Una composicion farmaceutica antiviral de uso topico
CONC2017/0011297A CO2017011297A2 (es) 2015-05-15 2017-11-02 Una composición farmacéutica antiviral de uso tópico
CL2017002796A CL2017002796A1 (es) 2015-05-15 2017-11-06 Una composición farmacéutica antiviral de uso tópico.
IL255635A IL255635A (en) 2015-05-15 2017-11-13 Antiviral pharmaceutical composition for topical use

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ARP150101519A AR100459A1 (es) 2015-05-15 2015-05-15 Una composición farmacéutica antiviral de uso tópico

Publications (1)

Publication Number Publication Date
AR100459A1 true AR100459A1 (es) 2016-10-05

Family

ID=57319498

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150101519A AR100459A1 (es) 2015-05-15 2015-05-15 Una composición farmacéutica antiviral de uso tópico

Country Status (11)

Country Link
US (1) US10478452B2 (es)
EP (1) EP3295934B1 (es)
AR (1) AR100459A1 (es)
BR (1) BR112017024399B1 (es)
CL (1) CL2017002796A1 (es)
CO (1) CO2017011297A2 (es)
ES (1) ES2915824T3 (es)
IL (1) IL255635A (es)
MX (1) MX384814B (es)
PE (1) PE20180396A1 (es)
WO (1) WO2016185069A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022060747A (ja) * 2020-10-05 2022-04-15 サンスター株式会社 抗ウイルス用口腔用組成物
CN117136064A (zh) * 2021-04-16 2023-11-28 株式会社日本触媒 抗冠状病毒剂
JP7627445B2 (ja) * 2021-04-16 2025-02-06 株式会社日本触媒 抗コロナウイルス剤

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3743727A (en) * 1970-11-16 1973-07-03 Crown Zellerbach Corp Enhancing tissue penetration of certain antimicrobial agents with dimethyl sulfoxide
US4902720A (en) * 1983-01-10 1990-02-20 Baldone Joseph A Treatment of virus infections with quaternary ammonium compounds
US5160737A (en) * 1988-05-03 1992-11-03 Perio Products Ltd. Liquid polymer composition, and method of use
DE60025837T2 (de) * 1999-09-24 2006-11-02 Janssen Pharmaceutica N.V. Antivirale feste dispersionen
US6855341B2 (en) 2002-11-04 2005-02-15 Jeffrey B. Smith Anti-viral compositions and methods of making and using the anti-viral compositions
US7968122B2 (en) * 2003-12-10 2011-06-28 Adventrx Pharmaceuticals, Inc. Anti-viral pharmaceutical compositions
ITMI20051417A1 (it) * 2005-07-22 2007-01-23 Mipharm S P A Formulazione topica in forma di gel contenente come ingredienti attivi ciclovit e lidocaina
US8119115B2 (en) * 2006-02-09 2012-02-21 Gojo Industries, Inc. Antiviral method
US7883487B2 (en) * 2008-06-16 2011-02-08 Shantha Totada R Transdermal local anesthetic patch with injection port
EP2691085A1 (en) * 2011-03-29 2014-02-05 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Film-forming composition for a ph-dependant sustained release of the active agent

Also Published As

Publication number Publication date
CL2017002796A1 (es) 2018-07-13
EP3295934B1 (en) 2022-03-02
EP3295934A4 (en) 2019-01-02
WO2016185069A1 (es) 2016-11-24
US10478452B2 (en) 2019-11-19
US20180250327A1 (en) 2018-09-06
PE20180396A1 (es) 2018-02-28
BR112017024399B1 (pt) 2022-06-07
MX2017014162A (es) 2018-06-20
EP3295934A1 (en) 2018-03-21
MX384814B (es) 2025-03-14
BR112017024399A2 (pt) 2019-02-05
ES2915824T3 (es) 2022-06-27
IL255635A (en) 2018-01-31
CO2017011297A2 (es) 2018-01-31

Similar Documents

Publication Publication Date Title
BR112015021709A2 (pt) poli(beta-amino éster)es modificados para administração de fármacos
CO2017011536A2 (es) Composiciones que comprenden una combinación de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo
MX392668B (es) Composiciones nasales de cannabidiol
BR112016006475A2 (pt) composição para cuidado dos cabelos e processo para fabricação da composição para o cuidado dos cabelos
BR112021002069A2 (pt) Composição para tratamento capilar, métodos e usos da mesma.
CL2017002767A1 (es) Nuevas proteínas específicas para cd137.
CL2017003436A1 (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso
MX2020006664A (es) Composiciones liquidas de suministro.
CY1120488T1 (el) Υγρη φαρμακευτικη συνθεση
MX387891B (es) Preparación inyectable que comprende una composición en gel de aripiprazol y polinilpirrolidona como agente de suspensión y el uso de la misma para tratar esquizofrenia, trastorno bipolar o depresión
BR112015017246A8 (pt) composição farmacêutica aquosa, seu uso e seringa
BR112018008601A2 (pt) composições compreendendo o canabidiol e segundos agentes terapêuticos para o tratamento de câncer
CO2023001953A2 (es) Compuestos fosfolípidos y usos de los mismos
PE20200338A1 (es) Composiciones cannabinoides novedosas y metodos para tratar la epilepsia infantil
MX392837B (es) Composiciones acidas de limpieza, sanitizacion y desinfeccion con nebulizacion reducida a traves del uso de polimeros de emulsion de agua en aceite de alto peso molecular.
BR112017026287A2 (pt) composições de hidroxipropil beta-ciclodextrina e métodos
MX2018016332A (es) Quimioterapias de combinacion.
BR112018003219A2 (pt) composição compreendendo pelo menos um tensoativo aniônico, pelo menos dois tensoativos não iônicos particulares, pelo menos um tensoativo anfotérico e pelo menos um polímero catiônico particular
CR20180014A (es) Composiciones de matriz polimérica tópicas que comprenden una alta concentración de hialuronato de sodio bio-fermentado y sus usos
BR112018010971A2 (pt) composição, métodos para preparar uma composição e para proteger dos raios do sol e uso de uma composição
BR112022012205A2 (pt) Compostos ativos para receptores nucleares
MX2017009482A (es) Formulación farmacéutica.
BR112019024667A2 (pt) Uso de um agente bioativo, e, de uma composição
MX375834B (es) Composición que comprende un agente de protección ultravioleta (uv), un polímero hidrófilo reticulado aniónico, un tensioactivo que tiene un equilibrio hidrofílico-lipofílico (hlb) menor de o igual a 5 y un copolímero de silicona.
BR112022008655A2 (pt) Composições de copolímero em bloco responsivas ao ph, micelas, e métodos de uso

Legal Events

Date Code Title Description
FB Suspension of granting procedure